Congenital adrenal hyperplasia (CAH) is commonly caused by mutations in genes encoding steroidogenic enzymes ([@B1], [@B2]). By contrast, the CAH variant P450 oxidoreductase (POR) deficiency (PORD) is due to mutations affecting POR that serves as mandatory electron donor enzyme to all microsomal cytochrome P450 (CYP) enzymes ([@B3]--[@B7]). Thus, in PORD, deficient steroidogenesis is caused by indirect impairment of key enzymes involved in glucocorticoid and sex steroid synthesis including 17α-hydroxylase (CYP17A1), 21-hydroxylase (CYP21A2), and also P450 aromatase (CYP19A1). Clinical manifestations of PORD include adrenal insufficiency and neonatal presentation with disordered sex development (DSD). Of note, DSD can occur in both sexes. Male undervirilization can be explained by impaired sex steroid synthesis, whereas 46,XX DSD despite low circulating androgens has been suggested to be explained by an alternative backdoor pathway to androgens active in fetal life, thereby leading to prenatal virilization of affected female PORD neonates ([@B4]).

PORD patients may present with a complex malformation phenotype resembling that described for Antley-Bixler syndrome (ABS; online inheritance in man no. 207410). However, an ABS phenotype can also be caused by *FGFR2* mutations ([@B7]) and furthermore has been observed in patients without evidence for *FGFR2* or *POR* mutations, suggesting hitherto unidentified genetic defects as underlying cause for the ABS presentation. The skeletal malformations observed in many but not all patients with PORD are thought to be due to disruption of enzymes involved in sterol synthesis, namely 14α-lanosterol demethylase (CYP51A1) and squalene epoxidase, and disruption of retinoic acid metabolism catalyzed by CYP26 isozymes ([@B8]) that also depend on electron transfer from POR ([@B9], [@B10]). Furthermore, *in vitro* activity of microsomal CYP enzymes involved in drug metabolism can be impaired by mutant POR ([@B11]). *In vivo* impairment, particularly of CYP3A4, has recently been demonstrated in a patient with PORD ([@B12]), which has important implications for steroid replacement and drug therapy in affected patients.

The clinical characteristics and corresponding genotypes have been described in a number of PORD patients ([@B3], [@B4], [@B6], [@B7], [@B13]--[@B18]). The mutation p.A287P is the most frequently reported mutation in patients of Caucasian origin ([@B3], [@B4], [@B7]), whereas p.R457H is most commonly found in the Japanese population ([@B7], [@B14], [@B16]). No PORD patient carrying null mutations on both alleles has been described so far, suggesting incompatibility of such genotype with postnatal life, similar to the observation of early fetal death in the murine *por* deletion model ([@B19], [@B20]).

Of note, the clinical presentation of PORD shows broad phenotypic variability, with adrenal insufficiency, DSD, and skeletal malformations present in some patients but not in others ([@B3], [@B7], [@B15], [@B17]). This calls for genotype-phenotype studies to aid in the prediction of disease manifestation and severity. However, apart from a large Japanese series of patients mainly carrying the p.R457H mutation in homozygous or compound heterozygous state ([@B14]), no report on a clinically well-characterized PORD patient cohort has addressed this important clinical issue systematically. Here we have analyzed a large mixed Caucasian PORD patient cohort, aiming to provide a comprehensive overview of the association of genotype with clinical and biochemical patient characteristics.

Patients, Materials, and Methods
================================

Patients
--------

The cohort consisted of 30 patients (27 unrelated) from 11 countries. Most patients were Caucasians. However, two patients were of Pakistani origin, one was Hispanic, and two had mixed Chinese/Hispanic and African/Caucasian backgrounds, respectively. Clinical assessment and serum biochemical analyses were performed by the local physicians.

Molecular genetic analysis
--------------------------

Genetic analysis of the *POR* gene was carried out after obtaining informed consent according to local institutional review board guidelines. DNA was extracted from peripheral blood leukocytes following a standard procedure. The coding sequence of the *POR* gene including exon-intron boundaries was amplified in 13 PCR fragments as previously described ([@B4]). Direct sequencing was carried out using an automated ABI3730 sequencer (Applied Biosystems Inc., Foster City, CA). Sequences were analyzed using the DNAStar Lasergene software package (DNASTAR Inc., Madison, WI). Sequence variants were designated according to Human Genome Variation Society recommendations ([www.hgvs.org/rec.html](http://www.hgvs.org/rec.html)) using the reference sequences GenBank [NC_000007](NC_000007) (g.DNA), GenBank [NM_000941.2](NM_000941.2) (c.DNA), and GenBank [NP_000932.3](NP_000932.3) (protein). For genomic DNA and c.DNA numbering, the nucleotide designated +1 was the A of the ATG start codon.

We used multiplex ligation-dependent probe amplification (MLPA) for the identification of partial or complete *POR* gene deletions or duplications. The MLPA assay was designed by MRC Holland (Amsterdam, The Netherlands) and comprises 16 probes each specifically detecting deletions of the 5′ untranslated exon (U1) and 14 of the 15 coding exons of the *POR* gene. The assay does not contain a probe for exon 11 because no stable signal was achieved. MLPA was performed using standard reaction conditions according to the manufacturer\'s protocol. Fragment analysis was conducted on an ABI 3130 Sequencer (Applied Biosystems) using the GeneMarker 1.7 software (SoftGenetics LLC, State College, PA).

*In vitro* analysis of novel POR mutations
------------------------------------------

Analysis of novel splice site mutations was performed *in silico*, using the NetGene2 online prediction tool ([www.cbs.dtu.dk/services/NetGene2/](http://www.cbs.dtu.dk/services/NetGene2/)). Functional analysis of novel missense mutations was performed using a microsomal yeast coexpression assay as previously described ([@B21]). In brief, POR mutations were generated by PCR-based site-directed mutagenesis, cloned into the yeast expression vector pYcDE2, and transformed into hCYP17A1-expressing yeast. Microsomes were prepared as previously described ([@B21]) and protein content measured by the Bradford method (Bio-Rad, Hemel Hempstead, UK). To confirm expression of equivalent amounts of proteins, Western blot analysis of the microsomes was performed using polyclonal antibodies to human POR (Abcam, Cambridge, UK) and human CYP17A1 (Santa Cruz Biotechnology, Middlesex, UK). CYP17A1 17α-hydroxylase and 17,20 lyase activities with either wild-type or mutant POR were assessed as previously described ([@B21]), and calculation of enzyme kinetic parameters and subsequent statistical analysis was performed using curve-fitting software (Enzfitter 2.0.9.1; Biosoft, Cambridge, UK).

Biochemical analysis of urine steroid hormone metabolites
---------------------------------------------------------

Analysis of urinary steroid metabolite excretion was performed by a quantitative gas chromatography/mass spectrometry (GC/MS) selected ion-monitoring method as described previously ([@B22]--[@B24]). In brief, steroids were enzymatically released from conjugation and, after extraction, chemically derivatized before GC/MS selected ion-monitoring analysis. Steroids quantified included metabolites of sex steroids, mineralocorticoids, glucocorticoids (cortisol and corticosterone), and their respective precursor steroids (Supplemental Table 1, published on The Endocrine Society\'s Journals Online web site at <http://jcem.endojournals.org>). Although numerous steroids (\>30) form part of a routinely measured panel, the data have been simplified for reporting by calculating substrate metabolite to product metabolite ratios. These ratios were developed to allow diagnosis of many steroidogenic disorders and in this instance calculated to define the impact of the *POR* mutations on distinct steroidogenic activities, as described previously ([@B25]). Steroid 21-hydroxylase activity was defined as the ratios of pregnanetriolone to cortisol metabolites \[100\*PT′ONE (pregnanetriolone)/(tetrahydrocortisone \[THE\]+tetrahydrocortisol \[THF\]+5αTHF)\] and 17-hydroxyprogesterone (17OHP) metabolites/cortisol metabolites \[(17-hydroxypregnanolone \[17HP\] + pregnanetriol \[PT\])/(THE+THF+5αTHF)\]. 17α-Hydroxylase activity was defined as the ratio of corticosterone metabolites over cortisol metabolites \[(tetra-11-dehydrocorticosterone \[THA\]+5αTHA+tetrahydrocorticosterone \[THB\]+5αTHB)/(THE+THF+5αTHF)\], and 17,20-lyase activity was assessed as the ratio of 17HP metabolites over androgen metabolites \[(17HP+PT)/(androsterone + etiocholanolone)\]. The ratio of the progesterone metabolite pregnanediol over cortisol metabolites \[PD/(THE+THF+ 5αTHF)\] was used as a PORD-specific diagnostic ratio. A second PORD-specific ratio has not been included here in aid of simplicity, although it is reported in other publications from our group. This is the ratio of the pregnenolone metabolite pregnenediol (5-pregnene-3β,20α-diol) to cortisol metabolites. This ratio is particularly valuable in diagnosing neonates and young infants in which 3β-hydroxy-Δ ([@B5]) steroids dominate.

PORD malformation score
-----------------------

Malformations observed in PORD include midface hypoplasia, craniosynostosis, phalangeal malformations (such as arachno-/campto-/clinodactyly, brachytelephalangia, rocker bottom feet), synostosis of large joints, and additional, nonskeletal malformations. We developed a malformation scoring system to assess the interindividual differences in the severity of skeletal malformations based on clinical and radiological assessments. This scoring system consists of six domains: midface hypoplasia, craniosynostosis, hand and feet malformations, large joint synostosis, femoral bowing, and the presence of additional malformations ([Table 1](#T1){ref-type="table"}). The minimal score is 0 (no malformations) and the maximum score of 16 indicates the highest possible severity. Information on malformations was requested from the referring clinician in a standardized fashion; subsequently, three clinicians independently scored each patient based on the information provided and agreed on a final score for each domain.

###### 

The six domains of the proposed PORD malformation score

  Score                  Midface hypoplasia                                                        Craniosynostosis                                                            Hand and feet malformations[*^a^*](#TF1-1){ref-type="table-fn"}   Large joint synostosis[*^b^*](#TF1-2){ref-type="table-fn"}     Femoral bowing                      Additional malformations
  ---------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------- --------------------------------------
  0                      None                                                                      None                                                                        None                                                              None                                                           None                                None
  1                      Moderate (low set ears, pear shaped nose)                                 Moderate (one suture affected, *e.g.* brachycephaly)                        One hand/feet malformation                                        Extension deficit                                              Present                             One additional malformation
  2                      Severe (compressed skeletal midface structure, proptosis)                 Severe (two or more sutures affected, *e.g.* turricephaly)                  Two hand/feet malformations                                       Fixed synostosis, joint contractures of one large joint        Complicated by neonatal fractures   Two or more additional malformations
  3                      Complicated by choanal stenosis/atresia that might require tracheostomy   Complicated by hydrocephalus, with ventriculoperitoneal shunt requirement   Three or more hand/feet malformations                             Fixed synostosis, joint contractures of several large joints                                       
  Maximum domain score   3                                                                         3                                                                           3                                                                 3                                                              2                                   2

The TMS ranged from a minimum of 0 to a maximum of 16 (TMS 0, no malformations; TMS 1--4, mild malformations; TMS 5--8, moderate malformations; TMS 9--16, severe malformations).

Phenotypic spectrum: arachnodactyly, clinodactyly, camptodactyly, metacarpal and metatarsal synostoses, wrist deviation, rocker bottom feet, talipes.

Predominantly radiohumeral and radioulnar malformations, but in more severe cases, also other joints including knees and ankles.

Results
=======

Spectrum of *POR* gene mutations
--------------------------------

Direct sequencing of the *POR* gene showed a variety of different molecular genetic defects including 14 novel mutations. These include three nonsense, three splice site, four frame shift, and one missense mutation as well as a 12-bp in-frame duplication ([Fig. 1](#F1){ref-type="fig"}, A and B, and [Table 2](#T2){ref-type="table"}). In addition, the patients harbored one previously described frame shift, one known nonsense, and seven known missense mutations. In four unrelated patients presenting with hallmark clinical and biochemical features of PORD, only one mutant allele was identified by direct sequencing; in two of these, MLPA detected a deletion of exons U1 and 1 and a partial duplication affecting exons 2--5, respectively (Supplemental Fig. 1). In two unrelated patients with classic clinical and biochemical PORD presentation, no *POR* mutation was detected either by direct sequencing or by MLPA analysis ([Table 3](#T3){ref-type="table"}).

![Localization of *POR* mutations at the DNA and protein level. A, Schematic representation of the *POR* gene. The untranslated exon U1 is given as a *black box* and coding exons are *numbered*. Novel mutations are given in *red font*, and the most common mutation p.A287P in exon 8 is marked in *blue*. Mutations cluster in the 3′ region without any additional common mutation apart from the p.A287P mutation. The partial deletion del ex U1--1 and the partial duplication dup ex2--5 that were identified by MLPA are represented by *labeled red boxes*. B, Schematic representation of the POR protein. Mutant residues are located in various locations all over the three functional domains of the POR protein. C, Three-dimensional POR protein model illustrating the localization of mutant residues in relation to the three functional moieties: nicotinamide adenine dinucleotide phosphate (NADPH; *blue*), flavin adenine dinucleotide (FAD; *yellow*), and flavin mononucleotide (FMN; *green*). Residues affected by missense mutations are given in *dark yellow*, frame shift mutations in *orange*, and residues affected by nonsense mutations as well as an in-frame duplication are marked in *red*.](zeg0021286050001){#F1}

###### 

Identified *POR* gene mutations on 54 unrelated alleles

  g.DNA position     Protein position   Location        Coding effect   Alleles   First published by
  ------------------ ------------------ --------------- --------------- --------- -----------------------
  Del ex U1--1                          Ex U1, 1        Deletion        1         Novel
  Dup ex 2--5                           Ex 2, 3, 4, 5   Duplication     1         Novel
  25,481dupA         p.Y87X             Ex 3            Nonsense        1         Novel
  26,404 A\>G        p.T142A            Ex 4            Missense        1         ([@B7])
  27,080 T\>G        p.Y181D            Ex 5            Missense        1         ([@B4])
  27,102_27,113dup   p.G188_V191dup     Ex 5            Duplication     1         Novel
  28,230 A\>T        IVS6 − 2A\>T       IVS 6           Splice site     1         Novel
  27,550 C\>T        p.R223X            Ex 6            Nonsense        1         Novel
  28,332 dupT        IVS7 + 2dupT       IVS 7           Splice site     2         Novel
  29,556 G\>C        p.A287P            Ex 8            Missense        23        ([@B3], [@B4])
  29,645 G\>A        IVS8 + 1G\>A       IVS 8           Splice site     1         Novel
  30,843dupC         p.Y376L*fsX74*     Ex 10           Frameshift      1         Novel
  31,146dupC         p.I444H*fsX6*      Ex 11           Frameshift      1         ([@B6])
  31,180 delC        p.Q455R*fsX90*     Ex 11           Frameshift      1         Novel
  31,187 G\>A        p.R457H            Ex 11           Missense        2         ([@B3], [@B4], [@B6])
  31,603_31,604del   p.V472A*fsX102*    Ex 12           Frameshift      1         Novel
  s31,681G\>C        p.R498P            Ex 12           Missense        2         Novel
  31,967G\>A         p.C569Y            Ex 13           Missense        1         ([@B3], [@B4])
  31,988dupA         p.Y576X            Ex 13           Nonsense        1         Novel
  32,062delG         p.E601S*fsX12*     Ex 13           Frameshift      1         Novel
  32,171 G\>A        p.Y607C            Ex 14           Missense        1         ([@B31], [@B32])
  32197C\>T          p.R616X            Ex 14           Nonsense        1         ([@B7])
  32,234 A\>C        p.H628P            Ex 14           Missense        1         ([@B21])
  Not detected                                                          6         

Ex, Exonic location; IVS, intervening sequence (designates intronic location).

###### 

Summary of clinical, genetic, and serum biochemical characteristics of PORD patients (n = 30)

  Patient no.                                                                Country of origin   Mutation on maternal allele   Mutation on paternal allele   Age at presentation   Karyotype   DSD (virilization/undermasulinization)   CYP17/CYP21 deficiency (GC/MS)   Increased baseline 17OHP   Baseline cortisol (nmol/liter)   Maximum cortisol after ACTH (nmol/liter)   Glucocortioid replacement
  -------------------------------------------------------------------------- ------------------- ----------------------------- ----------------------------- --------------------- ----------- ---------------------------------------- -------------------------------- -------------------------- -------------------------------- ------------------------------------------ ---------------------------
  P01*^[a](#TF3-1){ref-type="table-fn"},[b](#TF3-2){ref-type="table-fn"}^*   PL                  R457H                         A287P                         16 yr                 XX          Y                                        Y                                26                         290                              436                                        \+
  P02                                                                        PL                  ---                           ---                           NN                    XX          Y                                        Y                                43                         745                              866                                        −
  P03[*^a^*](#TF3-1){ref-type="table-fn"}                                    D                   C569Y                         Y181D                         NN                    XX          Y                                        Y                                5                          291                              280                                        \+
  P04[*^a^*](#TF3-1){ref-type="table-fn"}                                    D                   C569Y                         Y181D                         NN                    XY          N                                        Y                                49                         203                              316                                        \+
  P05[*^c^*](#TF3-3){ref-type="table-fn"}                                    D                   A287P                         ---                           NN                    XX          Y                                        Y                                20                         n/a                              127                                        ++
  P06[*^c^*](#TF3-3){ref-type="table-fn"}                                    USA                 A287P                         IVS6 − 2A\>T                  NN                    XX          N                                        Y                                n/a                        462                              512                                        \+
  P07[*^c^*](#TF3-3){ref-type="table-fn"}                                    USA                 A287P                         IVS6 − 2A\>T                  NN                    XY          Y                                        ND                               16                         253                              536                                        \+
  P08[*^a^*](#TF3-1){ref-type="table-fn"}                                    D                   A287P                         A287P                         NN                    XY          N                                        Y                                103                        165                              248                                        ++
  P09[*^c^*](#TF3-3){ref-type="table-fn"}                                    USA                 A287P                         V472A*fsX102*                 NN                    XY          Y                                        Y                                n/a                        209                              481                                        \+
  P10                                                                        UK                  Q455R*fsX544*                 IVS7 + 2dupT                  NN                    XY          Y                                        Y                                n/a                        142                              866                                        −
  P11[*^a^*](#TF3-1){ref-type="table-fn"}                                    USA                 A287P                         H628P                         NN                    XX          Y                                        Y                                31                         170                              209                                        ++
  P12[*^b^*](#TF3-2){ref-type="table-fn"}                                    PL                  A287P                         A287P                         12 yr                 XX          Y                                        Y                                72                         607                              717                                        −
  P13[*^c^*](#TF3-3){ref-type="table-fn"}                                    NL                  A287P                         Del ex U1--1                  NN                    XX          N                                        Y                                128                        140                              210                                        ++
  P14                                                                        UK                  A287P                         IVS8 + 1G\>A                  NN                    XX          Y                                        Y                                39                         n/a                              n/a                                        ++
  P15                                                                        USA                 A287P                         A287P                         NN                    XX          Y                                        Y                                n/a                        n/a                              n/a                                        ++
  P16                                                                        USA                 A287P                         A287P                         NN                    XY          N                                        Y                                747                        n/a                              n/a                                        ++
  P17                                                                        CAN                 A287P                         G188_V191dup                  NN                    XY          Y                                        Y                                n/a                        20                               209                                        ++
  P18                                                                        USA                 A287P                         A287P                         NN                    XX          Y                                        ND                               n/a                        121                              303                                        \+
  P19                                                                        PAK                 A287P                         I444H*fsX6*                   NN                    XY          Y                                        ND                               ND                         ND                               ND                                         ND
  P20[*^b^*](#TF3-2){ref-type="table-fn"}                                    ITA                 A287P                         A287P                         24 yr                 XX          Y                                        ND                               68                         149                              158                                        ++
  P21                                                                        AUT                 Y87X                          ---                           NN                    XX          Y                                        Y                                95                         n/a                              n/a                                        ++
  P22                                                                        MEX                 ---                           ---                           Stillborn             XX          Y                                        Y                                ND                         ND                               ND                                         ND
  P23[*^b^*](#TF3-2){ref-type="table-fn"}                                    AUS                 R457H                         Y576X                         NN                    XY          Y                                        Y                                112                        198                              229                                        ++
  P24[*^a^*](#TF3-1){ref-type="table-fn"}                                    PL                  Y607C                         E601S*fsX12*                  NN                    XY          Y                                        Y                                10                         391                              494                                        \+
  P25                                                                        PAK                 R498P                         R498P                         NN                    XX          Y                                        Y                                n/a                        495                              548                                        \+
  P26[*^b^*](#TF3-2){ref-type="table-fn"}                                    NL                  Y376*LfsX74*                  T142A                         18 yr                 XX          N                                        Y                                25                         375                              395                                        \+
  P27                                                                        D                   A287P                         R616X                         NN                    XY          N                                        Y                                6                          115                              203                                        ++
  P28[*^b^*](#TF3-2){ref-type="table-fn"}                                    UK                  A287P                         IVS7 + 2dupT                  12 yr                 XY          N                                        Y                                14                         353                              411                                        \+
  P29[*^b^*](#TF3-2){ref-type="table-fn"}                                    D                   A287P                         R223X                         16 yr                 XX          Y                                        Y                                15                         190                              314                                        ++
  P30                                                                        NL                  A287P                         Dup ex 2--5                   31 yr                 XX          Y                                        Y                                20                         360                              350                                        \+

Glucocorticoid replacement is as follows: −, none; +, hydrocortisone cover in stress/intercurrent illness; ++, permanent hydrocortisone replacement; ND, no glucocorticoid replacement implemented as no live birth. NN, Neonatal; Y, yes; N, no; n/a, not available; ND, not done; PL, Poland; D, Germany; USA, United States of America; UK, United Kingdom; NL, The Netherlands; CAN, Canada; PAK, Pakistan; ITA, Italy; AUT, Austria; MEX, Mexico; AUS, Australia. Mutation: ---, Alleles without identified disease-causing mutation.

Patients whose geno- and phenotype was reported in a previous publication: P01 \[case 1 ([@B4])\], P03 \[case 2 ([@B4])\], P04 \[case 3 ([@B4])\]; P08 ([@B33]); P11 ([@B34]); and P24 ([@B32]).

Patients with a description of pubertal development in a previous publication ([@B18]): P01 (case 1), P12 (case 2), P20 (case 3), P26 (case 4), P29 (case 5), P23 (case 6), and P28 (case 7).

Patients with a description of clinical phenotype only in a previous publication: P13 \[case 2 ([@B22])\], P01 \[case 3 ([@B22])\], P06 \[case 4 ([@B22])\], P09 \[case 5 ([@B22])\], P3 \[case 6 ([@B22])\], P4 \[case 7 ([@B22])\]; P07 \[case 1 ([@B35])\], P06 \[case 2 ([@B35])\]; and P05 ([@B36]).

The missense mutation p.A287P (g.29,556G\>C) was the most common point mutation, detected in 23 of 54 unrelated alleles (43%). Six patients (five unrelated) carried p.A287P on both alleles and one unrelated patient was homozygous for the novel point mutation p.R498P; the remaining 23 patients (21 unrelated) were compound heterozygous. The missense mutation p.R457H (g.31,187G\>A) was found on two unrelated alleles in patients of Polish and mixed Chinese/Hispanic origin, respectively. A splice site mutation in intron 7 (IVS7 + 2dupT) was detected in two unrelated patients. All other mutations were identified only in single families ([Table 3](#T3){ref-type="table"}). Apart from p.A287P, no other frequently occurring mutation was identified. However, mutations clustered in the 3′ portion of the *POR* gene, with their translation impacting on the flavin adenine dinucleotide and nicotinamide adenine dinucleotide phosphate binding domains of the POR protein ([Fig. 1](#F1){ref-type="fig"}, B and C).

Functional analysis of novel mutants
------------------------------------

Results of the *in silico* analysis of the three novel splice site mutations (Supplemental Table 2) confirmed complete loss of predicted *POR* wild-type splice donor and acceptor sites, respectively, and thus loss of POR function. Confidence values for the wild-type sequence predicting splicing ranged between 0.95 and 0.99, indicative of a high accuracy of prediction.

*In vitro* functional analysis of p.R498P and p.G188_V191dup confirmed reduction of CYP17A1 17α-hydroxylase activity to 66 and 37% of wild-type catalytic efficiency \[maximum enzyme velocity (Vmax)/Michaelis-Menten constant (Km)\], respectively. Coexpression of both mutants with human CYP17A1 reduced the maximal velocity of the enzymatic reaction, whereas the Michaelis constant remained essentially unaltered. Impairment of 17,20 lyase by displayed a similar pattern, consequently decreasing catalytic efficiency to 58 and 70% of wild type (Supplemental Table 3).

Urinary steroid profiling
-------------------------

In 25 patients the diagnosis of PORD had been established employing urinary steroid profiling by GC/MS; detailed results were available in 23 of them. Five established diagnostic substrate to product steroid metabolite ratios were applied to measure the impact on specific steroidogenic enzymes, namely 17α-hydroxylase and 21-hydroxylase ([Fig. 2](#F2){ref-type="fig"}). All five diagnostic ratios were increased above the normal reference range in 16 of 23 patients; an additional four had four of five ratios pathologically increased ([Fig. 2](#F2){ref-type="fig"}).

![*In vivo* steroidogenic enzyme activities in PORD patients (n = 23) as determined by urinary steroid profiling. Diagnostic steroid substrate over product ratios reflective of distinct steroidogenic enzyme activities and measured by GC/MS are shown in comparison with an age-matched reference cohort. *Box plots* represent the interquartile ranges (25th to 75th percentile), whiskers the fifth and 95th percentiles, respectively, of the reference cohort; each PORD case is represented by *specific symbols*.](zeg0021286050002){#F2}

Adrenal insufficiency
---------------------

The outcome of adrenal function assessment by a short cosyntropin test was documented in 27 patients, and 24 were found to have adrenal insufficiency ([Table 3](#T3){ref-type="table"}). Of those, 13 received permanent hydrocortisone replacement, whereas the remaining 11 were treated with hydrocortisone cover during intercurrent illness and surgical stress ([Table 3](#T3){ref-type="table"}). Only three patients showed a sufficient cortisol response to ACTH stimulation; one of these patients, P10, had shown normal values for both urinary steroid metabolite ratios reflective of 21-hydroxylase activity ([Fig. 2](#F2){ref-type="fig"}). Of note, there was no correlation between *POR* genotype and the presence and severity of glucocorticoid deficiency.

Baseline 17OHP concentrations were available in 21 patients and increased in all but one patient, with a wide range of 17OHP concentrations \[median 31 nmol/liter (942 ng/dl), range 5--747 nmol/liter (162--24,651 ng/dl)\] ([Table 3](#T3){ref-type="table"}). However, in the majority of patients, apart from one patient (P16), serum 17OHP levels were only mildly elevated and considerably lower than typically observed in classic 21-hydroxylase deficiency due to mutant CYP21A2.

Genital phenotype
-----------------

The majority of patients (70%) presented with either 46,XX DSD (15 of 18; 83%) or 46,XY DSD (seven of 12; 58%). However, patients of both sexes also presented with normal genital appearance consistent with their chromosomal sex (three females and six males), all of whom carried one major loss-of-function mutation. By contrast, all 12 patients with homozygous or compound heterozygous missense mutations presented with 46,XX DSD and normal male genital appearance in 46,XY individuals. Six patients were homozygous for p.A287P; all four 46,XX individuals presented with 46,XX DSD, whereas the two 46,XY individuals had normal male external genitalia. Intronic splice site mutations were of intermediate effect, largely defined by the mutation severity on the other allele ([Table 3](#T3){ref-type="table"} and Supplemental Table 4).

Malformation phenotype
----------------------

The majority of patients with no, mild \[total malformation score (TMS) 1--4)\], to intermediate malformations (TMS 5--8) were compound heterozygous or homozygous for two missense mutations ([Table 4](#T4){ref-type="table"}). By contrast, all patients with more severe malformations (TMS 9--16) were compound heterozygous, carrying a null mutation on one allele ([Table 4](#T4){ref-type="table"}). None of the patients with mild to intermediate malformations reached a maximal domain score for midface hypoplasia, craniosynostosis, or synostosis of the large joints. The most variable presentations were observed for hand and feet malformations, which were severe in some patients with otherwise mild malformation phenotype and vice versa ([Table 4](#T4){ref-type="table"}). All patients homozygous for p.A287P had mild to moderate malformations, with total malformation scores varying between 4 and 8, and none of these patients had a maximum score in any of the malformation domains, indicating the absence of severe malformations and their complications.

###### 

POR genotype and malformation type and severity in the PORD cohort (n = 29)

  TMS   Mutant allele 1   Mutant allele 2   Patient no.   Midface hypoplasia   Craniosynostosis   Phalangeal malformations   Large joint synostosis   Femoral bowing   Additional malformations   Type of additional malformation
  ----- ----------------- ----------------- ------------- -------------------- ------------------ -------------------------- ------------------------ ---------------- -------------------------- ------------------------------------------------------------------
  0     Y181D             C569Y             P4            0                    0                  0                          0                        0                0                          
  0     Y87X              ---               P21           0                    0                  0                          0                        0                0                          
  1     Y607C             E601S*fsX12*      P24           1                    0                  0                          0                        0                0                          
  4     A287P             R457H             P01           1                    0                  2                          0                        0                1                          Scoliosis
  4     A287P             Del ex U1--1      P13           2                    0                  0                          2                        0                0                          
  4     Y181D             C569Y             P03           1                    0                  3                          0                        0                0                          
  4     A287P             A287P             P08           1                    2                  1                          0                        0                0                          
  5     A287P             A287P             P12           1                    1                  2                          1                        0                0                          
  5     T142A             Y376L*fsX74*      P26           2                    0                  3                          0                        0                0                          
  5     A287P             A287P             P20           1                    0                  3                          0                        0                1                          Scoliosis
  5     A287P             IVS7 + 2dupT      P28           3                    1                  0                          1                        0                0                          
  5     A287P             Dup ex 2--5       P30           2                    0                  2                          1                        0                0                          
  6     ---               ---               P02           2                    1                  1                          0                        1                1                          Dysplastic ears
  6     A287P             R223X             P29           3                    1                  0                          2                        0                0                          
  7     A287P             H628P             P11           2                    1                  1                          2                        0                1                          Scoliosis
  7     R498P             R498P             P25           2                    0                  2                          2                        1                0                          
  7     A287P             A287P             P15           2                    2                  1                          2                        0                0                          
  8     A287P             A287P             P16           2                    2                  2                          1                        0                1                          Pectus excavatum
  8     A287P             R616X             P27           2                    2                  1                          3                        0                0                          
  9     A287P             ---               P05           2                    2                  2                          3                        0                0                          
  9     A287P             IVS8 + 1G\>A      P14           2                    2                  2                          3                        0                0                          
  9     A287P             G188_V191dup      P17           3                    0                  2                          0                        2                2                          Absent left kidney, frontal capillary hemangioma
  10    A287P             I444H*fsX6*       P19           3                    3                  0                          2                        1                1                          Scoliosis
  10    A287P             V472A*fsX102*     P09           2                    2                  2                          3                        0                1                          Two-vessel umbilical cord
  13    R457H             Y576X             P23           3                    2                  3                          3                        0                2                          Scoliosis, preauricular pits
  14    ---               ---               P22           2                    2                  3                          3                        2                2                          
  15    A287P             IVS6 − 2A\>T      P06           3                    3                  3                          2                        1                3                          Anteriorly placed anus, single umbilical artery, dysplastic ears
  15    A287P             IVS6 − 2A\>T      P07           3                    3                  3                          3                        2                1                          Dysplastic ears
  15    Q455R*fsX544*     IVS7 + 2dupT      P10           3                    3                  3                          3                        2                1                          Arnold-Chiari malformation

For definition of PORD malformation score, please see [Table 1](#T1){ref-type="table"}. Mutation: ---, Alleles without identified disease-causing mutation.

Discussion
==========

PORD manifests with a wide range of clinical signs and symptoms, and our study shows a broader phenotypic expression in Caucasian patients than previously observed in a large Japanese cohort ([@B3], [@B7], [@B14], [@B15]). This is mainly attributable to a greater variety of detected *POR* mutations. In this cohort containing the largest number of well-described Caucasian PORD patients to date, we validated the previous notion that p.A287P is the most prevalent mutation in Caucasians. Using MLPA, we were able to identify a partial deletion (exons U1--1), also previously described elsewhere ([@B14]), and for the first time a partial duplication (exons 2--5) of the *POR* gene on alleles with no mutation detected by direct sequencing. This illustrates that MLPA is a highly useful addition to the genetic work-up in PORD. However, despite using MLPA, we did not detect mutations on 11% of unrelated alleles. In a Japanese PORD cohort ([@B14]), no mutations were identified in 5% unrelated alleles (three of 58) in a largely Caucasian cohort ([@B7]) in 26% of alleles (12 of 46).

Our data illustrate that urinary steroid metabolite profiling by GC/MS can be considered a valuable noninvasive tool for the comprehensive diagnosis of PORD with clear diagnostic criteria. Applying diagnostic steroid substrate to product ratios can establish an unambiguous diagnosis of PORD and also provides insight into the differential impairment of steroidogenic enzyme function by mutant POR. Although the data in our study were based on 24-h urine collections, similar information can be obtained from a GC/MS analysis of spot urines ([@B25]). Obviously the diagnosis of PORD can also be established by the combined measurement of serum pregnenolone, progesterone, and 17-hydroxypregnenolone before and after ACTH stimulation ([@B15]).

GC/MS analysis can also be instrumental in analyzing the differential effects of POR mutations on different steroidogenic CYP enzymes. We have demonstrated this in a previous study by describing significantly increased corticosterone over cortisol metabolite ratios in patients with homozygous p.A287P ([@B21]). These *in vivo* findings were entirely consistent with the *in vitro* findings that indicated a significantly higher impairment of 17α-hydroxylase over 21-hydroxylase for p.A287P ([@B21]).

Based on clinical presentation and steroid measurements, some cases of PORD have previously been mistakenly diagnosed as 21-hydroxylase deficiency, aromatase deficiency ([@B16]), or even isolated 17,20 lyase deficiency ([@B17]). It is particularly important to consider PORD in the differential diagnosis of 21-hydroxylase deficiency because some of the previously described cases have been detected in 21-hydroxylase newborn screening programs ([@B3], [@B14]). In our cohort, serum 17OHP was increased in almost all patients but to considerably lower levels than usually observed in classic 21-hydroxylase deficiency. Establishing the correct diagnosis has significant consequences for the choice of glucocorticoid dose because PORD patients require only glucocorticoid replacement, whereas 21-hydroxylase-deficiency patients usually require higher glucocorticoid doses to control the concomitant adrenal androgen excess. The degree of 17-hydroxylase impairment observed in our PORD patients determined by the corticosterone metabolite to cortisol metabolite ratio \[(THA+5αTHA+THB+5αTHB)/(THE+THF+5αTHF; median 0.95, range 0.12--1.8)\] is significantly lower than previously observed in patients with 17-hydroxylase deficiency due to inactivating *CYP17A1* mutations \[(THA+5αTHA+THB+5αTHB)/(THE+THF+5αTHF); median 95, range 64--11\] ([@B26]). Similarly, the diagnostic steroid ratio indicative of 21-hydroxylase deficiency \[17OHP over cortisol metabolites, (17HP+PT)/(THE+THF+5αTHF\] has been shown to be increased above 10 in patients with classic CAH due to mutant *CYP21A2* and above 0.34 in nonclassic 21-hydroxylase deficiency patients ([@B23]). In our PORD cohort, this ratio has a median of 0.52 (range 0.04--1.20), an excellent fit with the serum 17OHP concentrations in our PORD patients, which largely varied within the range observed for nonclassic 21-hydroxylase deficiency patients.

The overwhelming majority of our PORD patients had adrenal insufficiency manifesting with isolated glucocorticoid deficiency, as documented by cosyntropin testing, and required either permanent hydrocortisone replacement or at least stress dose cover. In contrast to other reports ([@B3], [@B6], [@B7], [@B13]), none of our patients presented with clinical signs and symptoms of adrenal insufficiency, and several of our patients ([@B18]) underwent only formal testing many years after presenting with DSD and/or skeletal malformations. Random baseline cortisol is not a sensitive tool for detection of adrenal insufficiency, and therefore, it is mandatory to assess adrenal function by measuring serum cortisol before and after ACTH, which is the accepted standard for the diagnosis of adrenal insufficiency ([@B27], [@B28]). This is particularly true in PORD patients who often have normal basal cortisol secretion but fail to increase cortisol production in response to ACTH and thus are prone to deterioration during intercurrent illness.

Mineralocorticoid deficiency is not part of the biochemical presentation in PORD. By contrast, as demonstrated by the steroid metabolome analysis in our cohort, elevated corticosterone metabolites indicative of relative mineralocorticoid precursor excess are a frequent finding in PORD. We previously demonstrated predominant 17α-hydroxylase over 21-hydroxylase impairment by p.A287P ([@B21]), and indeed, arterial hypertension has been documented in homozygous carriers ([@B3], [@B12]), probably caused by excess deoxycorticosterone production as in classical 17α-hydroxylase deficiency. Systematic analysis of blood pressure should therefore become an integral part of clinical monitoring in PORD.

Genotype-phenotype correlations with regard to DSD presentation in PORD are most puzzling, and in our study we found DSD in both 46,XX and 46,XY individuals but also normal genital development in individuals of both sexes. A study performed in Japan showed a predominance of 46,XX DSD over 46,XY DSD, with 100% of 46,XX DSD but only 44% of 46,XY DSD patients classified as any genital feature at birth ([@B14]). Our findings are similar, despite a completely different and diverse ethnic/racial background in our population: more than 80% of our 46,XX patients presented with DSD, whereas DSD was present in only half of affected 46,XY individuals (Supplemental Table 3). The Japanese data suggest that p.R457H might be associated with virilization in 46,XX patients but most likely results in normal male genital development ([@B14]). Before our study only two p.A287P homozygous patients have been described; one with an unclear karyotype and genital appearance ([@B7]) and the other with ambiguous genitalia and 46,XY DSD ([@B3]). Our data based on six carefully characterized patients carrying homozygous p.A287P reveal p.A287P as associated with 46,XX DSD in four of four 46,XX individuals and with normal male genitalia in two of two 46,XY individuals.

It has been previously suggested that impairment of CYP19A1 aromatase activity by mutant POR may be responsible for the 46,XX DSD presentation in PORD because inactivating CYP19A1 mutations result in female virilization. However, if the classic androgen pathway via dehydroepiandrosterone is down-regulated due to significantly impaired 17,20 lyase activity in PORD patients, then there would not be a relevant amount of substrate for CYP19A1 to make this matter. Moreover, a previous *in vitro* study found that p.A287P does not impair CYP19A1 activity, but p.R457H abolishes aromatase activity ([@B29]). However, both mutations result in 46,XX DSD when present in the homozygous state, thus precluding a significant influence of aromatase on the 46,XX DSD phenotype. We have previously suggested that 46,XX DSD in PORD occurs through androgen generation via the alternative androgen synthesis pathway ([@B4]). This pathway also involved CYP17A1 17,20 lyase activity, and it has been previously shown that the CYP17A1 enzyme has a higher substrate preference for the alternative pathway over the classic pathway steroid substrates for its 17,20 lyase reaction ([@B30]). Thus, one could speculate that p.A287P and p.R457H associated with 46,XX DSD might have a high residual activity in the alternative pathway, whereas p.H628P, shown to result in 46,XY DSD in our cohort, may have low residual activity, a hypothesis to be explored by future studies.

PORD-associated malformations have previously been reported only in a qualitative fashion. To more objectively assess the spectrum and quantify the severity of malformations in PORD patients, we developed a novel scoring system to standardize malformation assessment reported in this study. Our data provide the basis for an improved detection and more accurate assessment of PORD-associated malformations based on clinical and radiological assessment, thereby facilitating early diagnosis and genetic counseling. Although PORD patients without obvious malformations have been described ([@B3], [@B7], [@B17]), it is possible that mild malformations may be overlooked. In several of our patients, neonatal assessment had not revealed obvious abnormalities, but careful reassessment after the diagnosis of PORD established the existence of several malformations, mostly affecting the midface, fingers, and toes. We found that patients with an absent or mild to moderate skeletal malformation phenotype were either homozygous or compound heterozygous for missense mutations, whereas severe malformations were invariably associated with a major loss-of-function mutation on one of the affected alleles ([Table 4](#T4){ref-type="table"}).

The 46,XY individuals with DSD showed a trend toward higher malformation scores (Supplemental Fig. 2), possibly suggesting that more severe mutations equally disrupt sex steroid synthesis and bone development. Interestingly, the patient with the most severe malformation score, P10, presented with 46,XY DSD but had a normal cortisol response to ACTH, nicely illustrating that a distinct POR mutation can have very different effects on different electron-accepting CYP enzymes.

In conclusion, we have described detailed clinical, biochemical and genetic findings in a large Caucasian PORD cohort. We have established the usefulness of MLPA as an addition to molecular genetic analysis of the *POR* gene. We provide a novel scoring system for standardized assessment of PORD-associated malformations. Major loss-of-function mutations on one of the affected alleles are associated with severe malformations, whereas homozygosity or compound heterozygosity for missense mutations predicts a mild to moderate malformation phenotype. Importantly, homozygosity for the most common mutation in Caucasians, p.A287P, allows for prediction of the genital phenotype and is associated with mild to moderate malformations. Adrenal insufficiency is present in the large majority of patients and cannot be predicted by genotype. Long-term follow-up of well-characterized patients will reveal the full extent of the impact of mutant POR on the health status of affected patients.
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======================

###### Supplemental Data

Abbreviations: ABSAntley-Bixler syndromeCAHcongenital adrenal hyperplasiaCYPcytochrome P450CYP17A117α-hydroxylaseCYP19A1P450 aromataseDSDdisordered sex developmentGC/MSgas chromatography/mass spectrometryMLPAmultiplex ligation-dependent probe amplification17OHP17-hydroxyprogesteronePORP450 oxidoreductasePORDPOR deficiencyTHAtetra-11-dehydrocorticosteroneTHBtetrahydrocorticosteroneTHEtetrahydrocortisoneTHFtetrahydrocortisolTMStotal malformation score.
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